Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report

The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasopoulou, Amalia, Gkoufa, Aikaterini, Diamantopoulos, Panagiotis, Kazanas, Spyridon, Eliadi, Irene, Samarkos, Michael, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295713/
https://www.ncbi.nlm.nih.gov/pubmed/35852114
http://dx.doi.org/10.2217/imt-2021-0331
_version_ 1784750107438088192
author Anastasopoulou, Amalia
Gkoufa, Aikaterini
Diamantopoulos, Panagiotis
Kazanas, Spyridon
Eliadi, Irene
Samarkos, Michael
Gogas, Helen
author_facet Anastasopoulou, Amalia
Gkoufa, Aikaterini
Diamantopoulos, Panagiotis
Kazanas, Spyridon
Eliadi, Irene
Samarkos, Michael
Gogas, Helen
author_sort Anastasopoulou, Amalia
collection PubMed
description The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combination with an investigational PEGylated interleukin (IL-2). We present the clinical characteristics and the laboratory and imaging findings of our patient during the course of COVID-19 pneumonia. Moreover, we discuss the currently available data regarding the mechanism of action of immune checkpoint inhibitors and IL-2 analogs in the treatment of COVID-19. The administration of these agents did not have a negative effect on the outcome of COVID-19 pneumonia in an elderly melanoma patient.
format Online
Article
Text
id pubmed-9295713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-92957132022-07-20 Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report Anastasopoulou, Amalia Gkoufa, Aikaterini Diamantopoulos, Panagiotis Kazanas, Spyridon Eliadi, Irene Samarkos, Michael Gogas, Helen Immunotherapy Case Report The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combination with an investigational PEGylated interleukin (IL-2). We present the clinical characteristics and the laboratory and imaging findings of our patient during the course of COVID-19 pneumonia. Moreover, we discuss the currently available data regarding the mechanism of action of immune checkpoint inhibitors and IL-2 analogs in the treatment of COVID-19. The administration of these agents did not have a negative effect on the outcome of COVID-19 pneumonia in an elderly melanoma patient. Future Medicine Ltd 2022-07-19 2022-06 /pmc/articles/PMC9295713/ /pubmed/35852114 http://dx.doi.org/10.2217/imt-2021-0331 Text en © 2022 Future Medicine Ltd https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Case Report
Anastasopoulou, Amalia
Gkoufa, Aikaterini
Diamantopoulos, Panagiotis
Kazanas, Spyridon
Eliadi, Irene
Samarkos, Michael
Gogas, Helen
Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title_full Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title_fullStr Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title_full_unstemmed Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title_short Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
title_sort clinical course of covid-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295713/
https://www.ncbi.nlm.nih.gov/pubmed/35852114
http://dx.doi.org/10.2217/imt-2021-0331
work_keys_str_mv AT anastasopoulouamalia clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT gkoufaaikaterini clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT diamantopoulospanagiotis clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT kazanasspyridon clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT eliadiirene clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT samarkosmichael clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport
AT gogashelen clinicalcourseofcovid19infectioninamelanomapatienttreatedwithnivolumabandbempegaldesleukinacasereport

Ejemplares similares